Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia‐inducible factor‐1 alpha
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Hypoxia‐inducible factor 1 (HIF‐1) plays an essential role in tumor angiogenesis and growth by regulating the transcription of several genes in response to hypoxic stress and changes in growth factors. This study was designed to investigate the effects of deguelin on tumor growth and angiogenesis, and the mechanisms underlying the antitumor activities of deguelin. We show here that orally administered deguelin inhibits tumor growth and blocks tumor angiogenesis in mice. Deguelin decreased expression of HIF‐1α protein and its target genes, such as VEGF, in a subset of cancer cell lines, including H1299 lung cancer cells, and vascular endothelial cells in normoxic and hypoxic conditions. Overexpression of vascular endothelial growth factor by adenoviral vector infection abolished the antiangiogenic effects of deguelin on H1299 nonsmall cell lung cancer cells. Deguelin inhibited de novo synthesis of HIF‐1α protein and reduced the half‐life of the synthesized protein. MG132, a proteasome inhibitor, protected the hypoxia‐ or IGF‐induced HIF‐1α protein from deguelin‐mediated degradation. Our findings suggest that deguelin is a promising antiangiogenic therapeutic agent in cancer targeting HIF‐1α. Considering that HIF‐1α is overexpressed in a majority of human cancers, deguelin could offer a potent therapeutic agent for cancer. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“Under normoxic conditions, HIF-a is subjected to prolyl hydroxylase-mediated hydroxylation within the oxygen-dependent degradation domain, which triggers binding of the VHL tumor suppressor protein and ubiquitin-mediated protein degradation.(2,3,5) In contrast, factor inhibiting HIF-mediated hydroxylation of HIF-a wit…”
BackgroundLando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 2×
“HIF-b is constitutively expressed, whereas the expression and activity of HIF-a protein are regulated by multiple oxygen-dependent and -independent mechanisms.4–6 Under normoxic conditions, HIF-a is subjected to prolyl hydroxylase-mediated hydroxylation within the oxygen-dependent degradation domain, which triggers bi…”
BackgroundLaughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 1×
“PI3K/ Akt activates mTOR (mammalian target for rapamycin), which phosphorylates and inactivates 4E-BP1 to connect the translational regulatory protein eIF-4E and thus to stimulate translation of HIF1a mRNA into protein.(8,43,44) Treatment with inhibitors of PI3K/ Akt, such as LY294002 and wortmannin, gene transfection…”
BackgroundTong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
Jiang, B.-H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17771 · Cited by 1,106 · cited 1×
“Disruption of HIF-1a transcriptional activity has shown therapeutic effects in xenograft models of colon and breast cancers.(48) Second, deguelin can affect multiple aberrant signaling components in cancer cells by virtue of its effects on the expression of HIF-1a and HIF-1 target genes in addition to its established…”
BackgroundHIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Loss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Han, J.-Y., Oh, S. H., Morgillo, F., Myers, J. N., Kim, E., Hong, W. K., & Lee, H.-Y. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji251 · Cited by 99 · cited 8×
“Tumor growth was assessed by measuring tumor size in two dimensions and calculating tumor volume as described elsewhere.(14,15) Histopathologic evidence of pulmonary toxicity (i.”
MethodInfluentialSelf-citation
Cited by
Anticancer Drugs Targeting the Mitochondrial Electron Transport Chain
Rohlena, J., Dong, L.-F., Ralph, S. J., & Neuzil, J. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3990 · Cited by 91
Min, S., Wang, X., Du, Q., Gong, H., Yang, Y., Wang, T., Wu, N., Liu, X., Li, W., Zhao, C., et al. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1763147 · Cited by 28
“IHC was performed on lung tumor sections from Kras transgenic animals and H1299 xenograft sections embedded in paraffin according to published reports.(18) Primary antibodies against cleaved caspase-3 (Cl-Cas3), HIF1α, Oct4, and CD34 were employed to assess levels of those proteins.”
MethodInfluentialAngeles, C. V., Velez, A., Rios, J., Laxa, B., Shum, D., Ruiz, P. D., Shen, Y., Ostrovnaya, I., Gularte-Mérida, R., Nacev, B. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2486 · Cited by 13
Metadata
- Authors
- Oh, S., Woo, J. K., Jin, Q., Kang, H., Jeong, J., Kim, K., Hong, W. K., & Lee, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-10-26
- Volume
- 122
- Issue
- 1
- Pages
- 5-14
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2053287288
- Cited by
- 80
- References
- 10
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.